KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39288737无 PMCID2024-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind, multicentre trial.Int J Antimicrob AgentsPMID 39293772无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.JAMA OncolPMID 39298144PMC114137522024-Nov0.95The study meets all criteria except for the requirement of a drug-containing intervention. The intervention is stereotactic body radiotherapy vs hypofractionated conventional radiotherapy, which is a non-drug radiation therapy comparison. Therefore, it is excluded.待处理
Association of Serum Biomarkers With Neurocognitive Decline After PCI in Small Cell Lung Cancer: An Exploratory Study of the Phase III NCT01780675 Trial.Clin Lung CancerPMID 39304362无 PMCID2024-Nov0.85The record is a secondary biomarker analysis from a definitive Phase III RCT in oncology but does not report any survival, progression, recurrence, death, hazard, or time-to-event efficacy outcome, which is required for inclusion.待处理
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.Lancet NeurolPMID 39307151无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.Lancet NeurolPMID 39307154无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.Diabetes Obes MetabPMID 39308336无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Nat MedPMID 39313594PMC115641012024-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.J DermatolPMID 39328096无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study.J DermatolPMID 39328126无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
The immunotherapy-based combination associated score as a robust predictor for outcome and response to combination of immunotherapy and VEGF inhibitors in renal cell carcinoma.Comput Biol Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39341105无 PMCID2024-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.J InfectPMID 39341405无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.Circ Heart FailPMID 39342655PMC115730602024-Nov0.98未发现恶性肿瘤人群证据。待处理
Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy.Jpn J OphthalmolPMID 39356386无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
The effect of YOCAS©® yoga on cancer-related fatigue and quality of life in older (60+) vs. younger (≤ 59) cancer survivors: Secondary analysis of a nationwide, multicenter, phase 3 randomized controlled trial.J Geriatr OncolPMID 39368335PMC118228542024-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.Alzheimers DementPMID 39369280PMC115678082024-Nov0.98未发现恶性肿瘤人群证据。待处理
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS DrugsPMID 39373844PMC114867932024-Nov0.98未发现恶性肿瘤人群证据。待处理
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.Ann Intern MedPMID 39374532PMC115736252024-Nov0.98未发现恶性肿瘤人群证据。待处理
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.Lancet Diabetes EndocrinolPMID 39374601无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study.Curr Med Res OpinPMID 39378042无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With Endometriosis-Associated Pain: Two Replicate Phase 3, Randomised, Double-Blind, Studies (SPIRIT 1 and 2).J Obstet Gynecol Neonatal NursPMID 39395815无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].ESMO OpenPMID 39418883PMC115324312024-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study.United European Gastroenterol JPMID 39452892PMC115788472024-Nov0.98未发现恶性肿瘤人群证据。待处理
Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.J Gynecol OncolPMID 39453395PMC115432492024-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.Cancer MedPMID 39527466PMC115526492024-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.Clin Transl SciPMID 39533519PMC115575122024-Nov0.95The study is oncology, human, randomized, Phase III, and has a drug intervention. However, it is a secondary pharmacokinetic-pharmacodynamic analysis of QT interval prolongation, which is a safety endpoint, not a time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria for the cohort.待处理
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial.JCO Glob OncolPMID 39541562无 PMCID2024-Nov0.95The study is a randomized, Phase III oncology trial with a drug intervention and reports original results. However, it is ineligible for this cohort because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or any Kaplan-Meier/HR analysis. The endpoints reported are response rates (DCR, ORR) and safety, which do not meet the cohort's inclusion criteria.待处理
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.Circ Cardiovasc ImagingPMID 39561225无 PMCID2024-Nov0.98未发现恶性肿瘤人群证据。待处理
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 38832972无 PMCID2024-Oct-310.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.BloodPMID 39082668PMC115518462024-Oct-310.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.N Engl J MedPMID 39476339无 PMCID2024-Oct-310.98未发现恶性肿瘤人群证据。待处理
Comparison of n-3 PUFA-Enriched vs. Olive-Oil-Based Lipid Emulsion on Oxidative Stress and Inflammatory Response in Critically Ill Post-Surgery Adults: Secondary Analysis of a Randomized Controlled Trial.Int J Mol SciPMID 39519287PMC115461872024-Oct-310.98未发现恶性肿瘤人群证据。待处理
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.Nat CommunPMID 39477924PMC115260182024-Oct-300.98未发现恶性肿瘤人群证据。待处理
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).Int J Mol SciPMID 39519198PMC115458442024-Oct-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Long-term follow-up of the conventional versus no-touch isolation technique for resection of primary colon cancer (JCOG1006): randomized clinical trial.BJS OpenPMID 39602807PMC116021312024-Oct-290.85The study is a Phase III randomized trial in oncology (colon cancer) with a primary time-to-event endpoint (disease-free survival). However, it compares two surgical techniques, not a drug-containing intervention versus control, and thus does not meet the drug-intervention criterion.待处理
Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial.HeartPMID 39401872无 PMCID2024-Oct-280.98未发现恶性肿瘤人群证据。待处理
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39426385无 PMCID2024-Oct-260.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 38924756无 PMCID2024-Oct-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.N Engl J MedPMID 39225278无 PMCID2024-Oct-240.98未发现恶性肿瘤人群证据。待处理
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).VaccinePMID 39241352无 PMCID2024-Oct-240.98未发现恶性肿瘤人群证据。待处理
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.J Immunother CancerPMID 39455094PMC115297472024-Oct-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.Signal Transduct Target TherPMID 39438467PMC114967322024-Oct-230.98未发现恶性肿瘤人群证据。待处理
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.BMJPMID 39442958PMC114977712024-Oct-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.Blood AdvPMID 38968156PMC114931912024-Oct-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.Sci RepPMID 39438591PMC114964952024-Oct-220.98未发现恶性肿瘤人群证据。待处理
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.Ann Rheum DisPMID 38955475PMC115031262024-Oct-210.95This is a Phase III randomized trial of olokizumab plus methotrexate for rheumatoid arthritis, not a human malignant neoplasm (cancer) trial. The primary efficacy endpoints are disease activity measures (ACR20/50/70, DAS28, CDAI, SDAI, HAQ-DI, Boolean remission), not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) for an oncology indication.待处理
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.Ann Rheum DisPMID 39159997PMC115030422024-Oct-210.98未发现恶性肿瘤人群证据。待处理
Effects of Gepirone-ER on Sexual Function in Patients With Major Depressive Disorder.J Clin PsychiatryPMID 39431906PMC114958462024-Oct-210.98未发现恶性肿瘤人群证据。待处理
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 10 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:非 KM 图;FIG 4.:非 KM 图;FIG A1.:研究设计图;另有 5 张未列出。PMID 38857463PMC114696302024-Oct-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
[Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study].Zhonghua Gan Zang Bing Za ZhiPMID 39528323PMC126772902024-Oct-200.98未发现恶性肿瘤人群证据。待处理